概括
米诺西迪尔作为心力衰竭患者的有效动脉血管扩张剂具有前景,具有强大,持久的效果,毒性可能比目前的治疗方法更低.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 目前用于慢性心力衰竭 (CHF) 的血管扩张剂具有局限性:酸盐主要是静脉扩张剂,普拉佐辛引起耐受性,而氨酸具有慢性毒性.
- 最佳的心血管衰竭管理需要有效的动脉扩张剂,具有更好的安全性.
研究的目的:
- 评估一剂米诺西迪尔在慢性左心室衰竭患者的急性血液动力学效应.
主要方法:
- 18名患有慢性左心室衰竭 (缺血性或初级心肌病) 的患者接受了单次口服剂量的米诺克西迪尔.
- 测量了血液动力学参数,包括心率,平均动脉压,心脏指数,全身血管阻力和各种压力.
- 峰值效应在5小时后被评估,效应至少在给药后8小时被监测.
主要成果:
- 米诺西迪尔显著增加心脏指数 (2.34到2.95 l/min/m2),并降低了全身血管阻力 (19.6到15.0单位).
- 观察到心率轻微增加 (85.4到90.9bpm) 和平均动脉压轻微下降 (88.0到84.9mm Hg).
- 米诺西迪尔没有显著改变右心房,肺动脉或肺压力,其影响持续至少8小时.
结论:
- 米诺西迪尔在心力衰竭患者中起到有效的动脉扩张作用,类似于拉,但潜在的效力和持续时间更大.
- 它的长时间作用和相对较低的急性毒性表明,米诺克西迪尔可能是治疗心力衰竭的宝贵血管扩张剂.
- 需要进一步评估米诺克西迪尔对心力衰竭的长期影响.
更多相关视频
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
相关概念视频
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
